Advertisement
UK markets closed
  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     
  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     
  • AIM

    755.28
    +2.16 (+0.29%)
     
  • GBP/EUR

    1.1672
    +0.0016 (+0.14%)
     
  • GBP/USD

    1.2482
    -0.0029 (-0.23%)
     
  • Bitcoin GBP

    51,032.13
    -382.24 (-0.74%)
     
  • CMC Crypto 200

    1,321.75
    -74.78 (-5.35%)
     
  • S&P 500

    5,104.04
    +55.62 (+1.10%)
     
  • DOW

    38,255.62
    +169.82 (+0.45%)
     
  • CRUDE OIL

    84.09
    +0.52 (+0.62%)
     
  • GOLD FUTURES

    2,348.90
    +6.40 (+0.27%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     
  • DAX

    18,161.01
    +243.73 (+1.36%)
     
  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     

Analysts’ Recommendations for Incyte in May

Analysts’ Recommendations for Incyte in May

Wall Street analysts expect the company to see a 40.9% rise in revenue to $459.8 million in Q2 2018. Incyte’s stock price has fallen nearly 51.7% over the last 12 months and nearly 29.6% in 2018 year-to-date. Wall Street analysts’ recommendations show a 12-month target price of $81.0 per share compared to its price of $66.67 per share on May 24.